Cyclodextrin polymers as nanocarriers for sorafenib

Valentina Giglio, Maurizio Viale, Vittorio Bertone, Irena Maric, Rita Vaccarone, Graziella Vecchio

Research output: Contribution to journalArticlepeer-review


Summary: Polymeric nanoparticles based on cyclodextrins are currently undergoing clinical trials as new promising nanotherapeutics. In light of this interest, we investigated cyclodextrin cross-linked polymers with different lengths as carriers for the poorly water-soluble drug sorafenib. Both polymers significantly enhanced sorafenib solubility, with shorter polymers showing the most effective solubilizing effect. Inclusion complexes between sorafenib and the investigated polymers exhibited an antiproliferative effect in tumor cells similar to that of free sorafenib. Polymer/Sorafenib complexes also showed lower in vivo tissue toxicity than with free sorafenib in all organs. Our results suggest that the inclusion of sorafenib in polymers represents a successful strategy for a new formulation of this drug.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalInvestigational New Drugs
Publication statusAccepted/In press - Nov 8 2017


  • Anticancer drug
  • Drug carriers
  • Nanoparticles
  • Solubility
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Cyclodextrin polymers as nanocarriers for sorafenib'. Together they form a unique fingerprint.

Cite this